Sana Biotechnology, Inc. Stock News

Tarbox Family Office Inc. reduced its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 33.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,000 shares of the companys stock after selling 1,000 shares during the quarter. Tarbox Family Office Inc.s holdings in Sana Biotechnology []

Sana Biotechnology (NASDAQ:SANA) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk. Earnings & Valuation This table compares Sana Biotechnology and Beam Therapeutics revenue, earnings per share []

Price T Rowe Associates Inc. MD reduced its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 1.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 1,190,199 shares of the companys stock after selling 16,511 shares during the period. Price T Rowe Associates Inc. MDs holdings in Sana Biotechnology were worth $23,399,000 at the []

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presen

Sana Biotechnology has a new $50 million tool in its toolbox.

Agreement combines Beam's gene editing technology with Sana's ex vivo platform

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast i

Two new Breakout Stocks for Week 34 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges® the portfolio is

Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies

Sana is the category leader for hypoimmune cell therapies that has the potential to transform diseases from oncology to CNS disorders and liver disease. Early data is promising, showing Sana's ability

First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression

SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be prese

SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast it

Presented key proof of concept data for multiple platforms at AACR 2021

— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes —